ESC TV Conversations - SGLT2 inhibitors – wonder drugs in Heart Failure and beyond?
ESC TV Conversations - SGLT2 inhibitors – wonder drugs in Heart Failure and beyond? Hosted by Carolyn Lam, Singapore With John McMurray, UK The video content has been made available for informational and educational purposes only and is aimed at a professional audience. It only represents the views and opinions of the original creators of such content. The information contained in the video has not been approved by the French National Agency for the Safety of Medicines and Health Products (ANSM). Always seek the advice of your physician or another qualified health care provider with any questions you may have regarding a medical condition. https://www.escardio.org/Congresses-&...
▶︎
ESC TV Conversations - Heart failure treatment 10 years from now
▶︎
Best Practices for Starting SGLT2 Inhibitors in HFpEF Treatment
▶︎
A Tale of Salt and Sugar: SGLT2 Inhibitors in Cardiovascular Disease
▶︎
How SGLT2 Inhibitors Protect The Kidney
▶︎
2023 ESC Guidelines Update: Acute & Chronic Heart Failure
▶︎
Sleep Doctor: If You Wake Up At 3AM, DO NOT Do This!
▶︎
What are SGLT2 inhibitors and how do they affect kidney disease?
▶︎
SGLT2 Inhibitors and Heart Failure
▶︎
ESC TV Conversations - The unknowns of atrial fibrillation – knowledge gaps in 2022
▶︎
Asprin Protects against HIGH Lp(a)? What the New Science Says
▶︎
The serendipitous story of SGLT2i in the treatment of heart failure
▶︎
The 2022 Guideline for the Management of Heart Failure: An Expert-Guided Tour
▶︎
How does Dapagliflozin work? Understanding SGLT2 inhibitors.
▶︎
EMPEROR Preserved | EMPEROR Pooled Trial Results
▶︎
Statins Exposed: Why the Evidence Doesn't Match the Hype
▶︎
Using SGLT2-inhibitors to treat cardiac patients with diabetes
▶︎
Keynote Presentation: Heart Failure with Reduced Ejection Fraction (G. MICHAEL FELKER, MD)
▶︎
Managing Heart Failure: Are SGLT2 Inhibitors the Next Leap Forward in Optimizing Patient Care?
▶︎
DAPA HF study results
▶︎